drugset
drugset / Trial / NCT02361034

To Evaluate Safety, Tolerability and Pharmacokinetics of GRC 27864 in Healthy Subjects and Elderly Healthy Subjects

NCT02361034 ↗

Phase 1 Completed 32 enrolled Glenmark Pharmaceuticals S.A.
RandomizedParallel-groupDouble-blindBasic science

Summary

This is a multiple Ascending dose (MAD) study with GRC 27864 in Healthy and Elderly Subjects.

Timeline

Start
2015-01
Primary completion
2015-09
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator GRC 27864 Unknown — Oral

Indications

No indication recorded.